Creating a Clear Path to Precision Oncology with Real-World Data
ViVE 2022 brought together thought leaders addressing key disparities and the future of healthcare. Our own C.K. Wang, alongside expert oncologists and technology innovators stressed the need for understanding what “precision oncology” really is.
Leading COTA into the Next Chapter of Data-Driven Precision Oncology
I’m delighted to be leading COTA at this pivotal moment in history, when precision oncology and data science are advancing together at lightning speed. By working with partners across the healthcare continuum, we can guide cancer patients and their families down the path to clear, safe, personalized, and effective cancer care.
Reality check: Real-world evidence to support therapeutic development in hematologic malignancies
In this article in the scientific journal Blood Reviews, COTA researchers and collaborators share their views on the many sources of RWD and how to assess fit-for-purpose for use in RWE generation. They also review promising use cases for RWD, particularly for hematologic malignancies.
To Help Accelerate Development of Cancer Treatments with Real-World Data, COTA Welcomes Kevin Schweikert as Vice President, Life Sciences
COTA is pleased to announce Kevin Schweikert has joined the company as vice president, life sciences. With more than 20 years of experience in life sciences business development, Kevin has partnered with the most innovative pharmaceutical companies in the business, and the vendors these companies turn to for real-world data and analytics.
From Regulatory to RWD: A Journey to Improve Cancer Care with COTA
Working with the FDA and now COTA Laura describes why real-world data is an integral part of today’s patient care.
COTA Promotes Paige Whitney to Senior Vice President to Expand the Use of Real-World Data in Life Sciences
Paige Whitney will join the executive leadership team as Senior Vice President of Life Sciences. Paige is responsible for growing the company’s industry partnerships and strengthening COTA’s position as a leading provider of oncology RWD.
The Roadmap for Making Clinical Trials More Diverse and Representative
Diversity in clinical trials is a change that needs to be made in order to make all efforts more efficient and develop a better ending result for patients. Karla Feghali and Laura Fernandes detail why this is so necessary moving forwards.
Real-World Data is Essential for Illuminating and Addressing Disparities in Care
RWD can help us address one of the most challenging systemic issues in healthcare: disparities in health outcomes perpetuated by uneven access to services and the unconscious bias of humans and technology
Patient-Centered Drug Development Leads the Way in 2022
This will be the year that patient centricity drives drug development and care delivery decisions.
Study: 83% of Oncologists Believe Real-World Data Is Critical to Accelerating Cancer Research and Treatment
Oncologists believe it is important for all clinical trials to include a real-world data component, and the overwhelming majority would urge pharmaceutical companies and cancer research groups to use real-world data in all clinical trials as well.
